Objective: Hearing aid amplification rationales have typically been developed by using global averages of the long-term average speech spectrum (LTASS) from Western European languages. However, there are few reports on hearing-aid amplification based on acoustic-phonetic characteristics of the Japanese language. This study's objective is to investigate the LTASS for Japanese, and to compare a typical amplification rationale originally developed mainly for Western European languages with an amplification rationale specifically adjusted to the LTASS for Japanese.
Methods: LTASS for two speech materials provided by four Japanese talkers were analyzed using 1/3 octave bandwidth filters. The speech was recorded with different levels of vocal effort, yielding three LTASS for "soft", "moderate" and "loud" speech. From these results, a gain offset of the hearing-aid amplification for Japanese was obtained as compared to ANSI S3.5. Speech intelligibility for an amplification rationale for Western European languages and the newly-developed Japanese version was obtained for presentation levels of 50 dB SPL, 65 dB SPL and 80 dB SPL. Nineteen people with mild to moderate hearing loss participated in the speech intelligibility experiment. Scores in% correct were arcsine-transformed and subjected to repeated measures ANOVA with pairwise comparisons of significant main effects using Bonferroni adjustments for multiple comparisons.
Results: The LTASS for Japanese was slightly different from the values of previous reports. A comparison of LTASS values to ANSI S3.5 with values for Japanese showed that the Japanese amplification rationale for "moderate" speech levels required more gain in the low-frequency area, and less gain in the high-frequency area. There was no significant difference in the speech intelligibility level between the amplification characteristics of Western European languages and Japanese language at each presentation level.
Conclusion: It was shown that for hearing-aid amplification for Japanese, adjustments based on LTASS differences for Western European Languages could be made. This preserved speech intelligibility at the same level as the original amplification rationale, suggesting that there was no need to consider differences in phonetics of Japanese to optimize speech understanding.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.anl.2021.04.011 | DOI Listing |
Medicine (Baltimore)
January 2025
Department of Pathology, Deyang Peoples' Hospital, Deyang, Sichuan Province, China.
Rationale: Ependymomas are commonly prevalent intramedullary neoplasms in adults, with hardly any cases of exophytic extramedullary ependymoma being reported. Meningiomas, on the contrary, are one of the most common intradural extramedullary (IDEM) tumors. However, the occurrence of both IDEM tumors simultaneously is extremely rare.
View Article and Find Full Text PDFTheranostics
January 2025
Department of Nephrology, China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Beijing, 100029, China.
The tertiary structure of normal podocytes prevents protein from leaking into the urine. However, observing the complexity of podocytes is challenging because of the scale differences in their three-dimensional structure and the close proximity between neighboring cells in space. In this study, we explored podocyte-secreted angiopoietin-like 4 (ANGPTL4) as a potential morphological marker via super-resolution microscopy (SRM).
View Article and Find Full Text PDFMed
January 2025
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; WIN Consortium, Paris, France; University of Nebraska, Omaha, NE, USA. Electronic address:
Tumor-agnostic US Food and Drug Administration approvals are transforming oncology. They include larotrectinib/entrectinib/repotrectinib (NTRK fusions), selpercatinib (RET fusions), dabrafenib/trametinib (BRAF mutations), pembrolizumab/dostarlimab (microsatellite instability), pembrolizumab (high tumor mutational burden), and trastuzumab deruxtecan (HER2 3+ expression) (all solid cancers). Pemigatinib is approved for FGFR1-rearranged myeloid/lymphoid neoplasms.
View Article and Find Full Text PDFMedicine (Baltimore)
December 2024
Department of Ultrasound, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Eur J Haematol
December 2024
Department of Pathology, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Multiple myeloma (MM) is an incurable blood malignancy characterized by the clonal expansion of plasma cells and the secretion of monoclonal immunoglobulins. High-risk MM, defined by specific cytogenetic abnormalities, poses significant therapeutic challenges and is associated with inferior survival outcomes compared to standard-risk disease. Although molecularly targeted therapies have shown efficacy in other hematologic malignancies, currently venetoclax is the only targeted therapy approved for MM (t(11;14)).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!